NASDAQ · Financial Statements

Harvard Bioscience, Inc. (HBIO) Revenue, Earnings & Financial Statements

$9.08 NASDAQ: HBIO Market Cap $41.52M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Harvard Bioscience, Inc. most recently reported annual revenue of $87.0M, a net loss of $57.0M. Revenue declined at an average annual rate of 3.1% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Harvard Bioscience, Inc.: Revenue fell from $105.0M in 2016 to $87.0M in 2025, a change of -17.1% over 9 years; net profit was positive in 0 of 10 reported years; operating margin moved from -2.9% to -0.7%, a shift of +2.1 percentage points; the most recent year shows a net loss of $57.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$105.0M$102.0M$121.0M$116.0M$102.0M$119.0M$113.0M$112.0M$94.0M$87.0M
Operating Expenses$108.0M$102.0M$120.0M$116.0M$102.0M$117.0M$120.0M$110.0M$100.0M$87.0M
Operating Profit−$3.0M$0$1.0M$0$0$2.0M−$7.0M$2.0M−$6.0M−$1.0M
Operating Margin-2.9%-0.1%0.8%0.3%0.2%1.7%-6.1%1.7%-6.6%-0.7%
Other Income$0−$2.0M−$9.0M−$6.0M−$8.0M−$2.0M−$2.0M−$4.0M−$5.0M−$57.0M
Interest$1.0M$1.0M$5.0M$5.0M$5.0M$2.0M$3.0M$4.0M$3.0M$5.0M
Depreciation$4.0M$3.0M$8.0M$8.0M$8.0M$8.0M$8.0M$7.0M$7.0M$6.0M
Profit Before Tax−$3.0M−$2.0M−$9.0M−$6.0M−$7.0M$0−$9.0M−$3.0M−$12.0M−$57.0M
Tax rate (%)-39.9%58.6%43.2%14.8%-7.1%-105.7%-3.7%-33.6%-6.3%1.2%
Net Profit−$4.0M−$1.0M−$3.0M−$5.0M−$8.0M$0−$10.0M−$3.0M−$12.0M−$57.0M
EPS−$1.30−$0.25−$0.95−$1.20−$2.00−$0.07−$2.30−$0.80−$2.80−$12.80

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$28.0M$25.0M$23.0M$22.0M$25.0M$22.0M$20.0M$21.0M$24.0M$21.0M$23.0M$22.0M
Operating Expenses$28.0M$27.0M$25.0M$24.0M$25.0M$71.0M$21.0M$20.0M$22.0M$21.0M$24.0M$23.0M
Operating Profit$0−$2.0M−$2.0M−$2.0M$0−$50.0M−$1.0M$0$2.0M$0−$1.0M−$1.0M
Operating Margin1.0%-9.3%-9.0%-8.5%0.0%-228.1%-4.0%1.0%8.1%-0.6%-4.3%-5.2%
Interest$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$1.0M$2.0M$2.0M$2.0M$2.0M
Profit Before Tax−$1.0M−$4.0M−$3.0M−$4.0M$1.0M−$51.0M−$2.0M−$1.0M−$3.0M−$3.0M−$3.0M−$3.0M
Tax rate (%)-64.8%-4.7%10.8%-6.9%97.0%0.9%-1.2%-8.6%11.1%-3.5%-0.5%2.7%
Net Profit−$2.0M−$5.0M−$3.0M−$5.0M$0−$50.0M−$2.0M−$1.0M−$3.0M−$3.0M−$3.0M−$3.0M
EPS−$0.43−$1.10−$0.67−$1.10$0.00−$11.40−$0.51−$0.28−$0.64−$0.77−$0.64−$0.58

Over the 10 years reported for Harvard Bioscience, Inc., borrowings increased from $14.0M in 2016 to $44.0M in 2025, cash stood at $9.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.18 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$108.0M$109.0M$168.0M$165.0M$156.0M$162.0M$145.0M$137.0M$127.0M$80.0M
Current Assets$45.0M$48.0M$55.0M$54.0M$52.0M$62.0M$51.0M$49.0M$45.0M$48.0M
Cash$6.0M$6.0M$8.0M$8.0M$8.0M$8.0M$5.0M$4.0M$4.0M$9.0M
Inventory$20.0M$21.0M$25.0M$22.0M$22.0M$28.0M$26.0M$25.0M$23.0M$21.0M
Receivables$20.0M$17.0M$21.0M$21.0M$18.0M$22.0M$17.0M$16.0M$15.0M$16.0M
Fixed Assets$4.0M$4.0M$6.0M$13.0M$12.0M$10.0M$9.0M$9.0M$11.0M$5.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$4.0M$0$0
Other Assets$38.0M$40.0M$57.0M$57.0M$59.0M$58.0M$56.0M$57.0M$56.0M$10.0M
Total Liabilities$36.0M$28.0M$86.0M$83.0M$80.0M$79.0M$73.0M$64.0M$63.0M$66.0M
Current Liabilities$15.0M$14.0M$22.0M$25.0M$21.0M$25.0M$23.0M$27.0M$55.0M$22.0M
Borrowings$14.0M$12.0M$61.0M$64.0M$58.0M$57.0M$54.0M$43.0M$44.0M$44.0M
Other Liabilities$22.0M$17.0M$25.0M$19.0M$22.0M$22.0M$19.0M$22.0M$19.0M$22.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$72.0M$81.0M$82.0M$82.0M$77.0M$83.0M$72.0M$73.0M$63.0M$14.0M

For Harvard Bioscience, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $6.0M; free cash flow was positive in 6 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$5.0M$1.0M$2.0M$8.0M$9.0M$1.0M$1.0M$14.0M$1.0M$7.0M
Investing Cash Flow−$3.0M−$2.0M−$54.0M−$1.0M−$3.0M−$3.0M−$3.0M−$4.0M−$5.0M−$3.0M
Financing Cash Flow$0$0−$2.0M$0−$1.0M−$4.0M−$1.0M−$2.0M$0$0
Net Cash Flow−$1.0M$0$2.0M$0$0$0−$3.0M$0$0$5.0M
Free Cash Flow$4.0M$0$1.0M$7.0M$8.0M$0$0$12.0M−$2.0M$6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-21.56
FCF Yield-7.74%
Quick Ratio0.86
Interest Coverage-0.08
Return 1Y61.90%
Return 3Y-78.46%
Return 5Y-88.04%

Harvard Bioscience, Inc. (HBIO) financials — frequently asked questions

What is Harvard Bioscience, Inc.'s annual revenue?

Harvard Bioscience, Inc. (HBIO) reported annual revenue of $87.0M in its most recent fiscal year.

What is Harvard Bioscience, Inc.'s net profit?

Harvard Bioscience, Inc. (HBIO) reported a net loss of $57.0M in its most recent fiscal year.

What is HBIO EV/EBITDA?

Harvard Bioscience, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -21.56. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Medical - Instruments & Supplies stocks

BDX revenue $19.5BMDLN stockWST revenue $3.1BSOLV revenue $8.3BBAX revenue $11.2BCOO revenue $4.1BRGEN revenue $738.0MAVTR revenue $6.6BATR revenue $3.8BBLCO revenue $5.1BAll Medical - Instruments & Supplies stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
HBIO Overview HBIO Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.